Description of Medical ServiceThis is a genomic test that predicts likelihood of response to adjuvant chemotherapy and 10-year cancer recurrence in patients with node-negative and node positive (1–3), oestrogen-receptor-positive(ER+), human epidermal growth factor receptor 2 negative(HER2-), invasive breast cancer.
Description of Medical ConditionOutside Australia, this test is currently used in women with node-negative and node positive (1-3), oestrogen-receptor-positive, HER2 negative invasive early stage breast cancer.
Reason for ApplicationNew MBS item
Medical Service TypeInvestigative
Previous Application NumberNot Applicable
PICO ConfirmationNo second PASC required
Final Protocol (PDF 1158 KB)
Final Protocol (Word 488 KB)
Public Summary DocumentFinal Public Summary Document (PDF 240 KB)
Final Public Summary Document (Word 138 KB)